Contineum Therapeutics, Inc. CTNM
Contineum Therapeutics, Inc. (Nasdaq: CTNM) is a respiratory drug developer. Its lead program, PIPE-791, is in Phase 2 for idiopathic pulmonary fibrosis (PROPEL-IPF Phase 2); also chronic pain.
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| PIPE-791 (LPAR1 antagonist) | idiopathic pulmonary fibrosis (Phase 2 PROPEL-IPF, ~324 patients, dosing began Q1 2026) | small molecule | Phase 2 |
| PIPE-307 / JNJ-89495120 (M1R antagonist, out-licensed to J&J) | major depressive disorder (J&J-sponsored Phase 2 Moonlight-1; enrollment completed June 2026) | small molecule | Phase 2 |
| PIPE-791 (LPAR1 antagonist) | chronic osteoarthritic pain / chronic low back pain (Phase 1b completed, positive topline April 2026) | small molecule | Phase 1 |
| CTX-343 | inflammatory/fibrotic disease (clinical development deferred pending funding) | small molecule | Pre-clinical |
Recent results and decisions
- Jul 30, 2026completed enrollment Johnson & Johnson completed enrollment of 107 participants in the Phase 2 MOONLIGHT-1 trial of PIPE-307/JNJ-5120 in MDD in June 2026.
Johnson & Johnson completed enrollment of 107 adult participants for its Phase 2 MOONLIGHT-1 trial of JNJ-5120/PIPE-307 in June 2026.
Filing - May 5, 2026met Exploratory randomized Phase 1b met its primary objective of safety and tolerability, with pain improvements numerically greater than placebo (no figures given); topline originally reported April 30, 2026.
The trial met its primary objective of assessing safety and tolerability, demonstrating an adverse event profile generally consistent with previous PIPE-791 clinical trials.
Filing - Mar 5, 2026started Patient dosing initiated in PROPEL-IPF, a global 26-week randomized Phase 2 trial of PIPE-791 in ~324 IPF patients (primary endpoint change in FVC).
Contineum has initiated patient dosing in PROPEL-IPF, a global Phase 2 clinical trial evaluating PIPE-791 for the treatment of patients with IPF.
Filing
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 2 respiratory companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.